Sunho Biologics, Inc. (HKG:2898)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
6.40
0.00 (0.00%)
At close: Mar 10, 2026
64.52%
Market Cap 971.95M
Revenue (ttm) 18.63K
Net Income (ttm) -89.95M
Shares Out 151.87M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 1,530
Open n/a
Previous Close 6.40
Day's Range n/a
52-Week Range 3.99 - 8.60
Beta n/a
RSI 48.11
Earnings Date Mar 31, 2026

About Sunho Biologics

Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer (CRC). The company also provides IAP0971 and IAE0972 immunocytokines, which have completed Phase I clinical trials for advanced solid tumors, i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 128
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2898
Full Company Profile

Financial Performance

In 2024, Sunho Biologics's revenue was 38,000, a decrease of -99.78% compared to the previous year's 17.53 million. Losses were -79.97 million, -39.74% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.